JOURNAL OF MEDICINAL CHEMISTRY

SE1 STOP

THARMACY USTAR

SEPTEMBER 4, 1992 VOLUME 35 • NUMBER 18 MERICAN CHEMICAL

DOCKET RM Find authenticated court documents without watermarks at docketalarm.com.

Α

JOURNAL OF MEDICINAL CHEMISTRY

EDITOR-IN-CHIEF

PHILIP S. PORTOGHESE

Department of Medicinal Chemistry College of Pharmacy, Room 8-114 University of Minnesota 308 Harvard St. S.E. Minneapolis, Minnesota 55455 (612) 624-6184 FAX (612) 626-6891

SENIOR EDITORS

Raymond E. Counsell Laurence H. Hurley Herbert T. Nagasawa Wendel L. Nelson

Book Review Editor Carl Kaiser

EDITORIAL ADVISORY BOARD

Stephen J. Benkovic Ronald T. Borchardt Arthur D. Broom James K. Coward Peter B. Dervan Stephen W. Fesik David S. Fries Ralph F. Hirschmann M. Ross Johnson SF15'92 Michael Marletta David A. Matthews **Duane Miller** John H. Musser John L. Neumeyer William Prusoff Kenner C. Rice C. H. Robinson Robert R. Ruffolo, Jr. Stuart Schreiber John A. Secrist, III Robert P. Sheridan David J. Triggle Daniel F. Veber Michael Williams Dennis M. Zimmerman Ex officio: William F. Johns

American Chemical Society 1155 16th St., N.W. Washington, DC 20036 (202) 872-4600 TDD (202) 872-8733 FAX (202) 872-4615

Journals Department

Μ

OCKF

American Chemical Society 2540 Olentangy River Road P.O. Box 3330 Columbus, OH 43210 (614) 447-3600, Ext. 3171 TELEX 6842086; FAX (614) 447-3745

Member & Subscriber Services

American Chemical Society P.O. Box 3337 Columbus, OH 43210 (614) 447-3776: FAX (614) 447-3671 Journal of Medicinal Chemistry (ISSN 0022-2623) is published biweekly by the American Chemical Society at 1155 16th St., N.W., Washington, DC 20036. Second-class postage paid at Washington, DC, and additional mailing offices. POSTMASTER: Send address changes to Journal of Medicinal Chemistry, Member & Subscriber Services, P.O. Box 3337, Columbus, OH 43210. Canadian GST Reg. No. R127571347.

PUBLICATIONS DIVISION Robert H. Marks, Director

Journals Department: Charles R. Bertsch, Head; Marianne C. Brogan, Associate Head

Editorial Office: Mary E. Scanlan, Manager; Kathleen E. Duffy, Joseph E. Yurvati, Journals Editing Managers; Anne C. O'Melia, Senior Associate Editor; Mary Jo Lesheski, Lee S. Thurston, and Margaret A. Winship, Assistant Editors

Advertising Office: Centcom, Ltd., 1599 Post Road East, P.O. Box 231, Westport, CT 06881

© Copyright 1992 by the American Chemical Society. **Copyright permission**: An individual may make a single reprographic copy of an article in this publication for personal use. Reprographic copying beyond that permitted by Section 107 or 108 of the U.S. Copyright Law is allowed, provided that the appropriate per-copy fee is paid through the Copyright Clearance Center, Inc., 27 Congress St., Salem, MA 01970. For reprint permission, please write to the Copyright Administrator, Publications Division, at the ACS Washington address.

The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

Editorial Information

Instructions for authors and copyright transfer form are printed in the first issue of each volume. Please conform to these instructions when submitting manuscripts.

Manuscripts for publication should be submitted to the Editor, Philip S. Portoghese, at his Minneapolis address.

Correspondence regarding accepted papers and proofs should be directed to the Journals Department, at the address below.

Page charges of \$25.00 per page may be paid for papers published in this journal. Payment does not affect acceptance or scheduling of papers.

Bulk reprints of individual articles are available. For information write to Distribution Office at the ACS Washington address.

The American Chemical Society and its Editors assume no responsibility for the statements and opinions advanced by contributors.

Registered names and trademarks, etc., used in this publication, even without specific indication thereof, are not to

Subscription and Business Information

1992 subscription prices, including postage. (For membership information, contact Office of Member Services at the ACS Washington address.)

				R. 1265	
	U.S.	Canada and Mexico	Europe*	All Other Countries*	
Printed					
Members-1 yr	\$ 49	\$ 80	\$108	\$131	
2 yr	\$ 88	\$150	\$206	\$252	
Nonmembers	\$497	\$528	\$556	\$579	
Microfiche					
Members-1 yr	\$ 49	\$ 49	\$ 69	\$ 69	
2 yr	\$ 88	\$ 88	\$128	\$128	
Nonmembers	\$497	\$497	\$517	\$517	
Supplementary material (microfiche)	\$ 30	\$ 45	\$ 45	\$ 45	
* Air service includ	led.			7 ²¹	

New and renewal subscriptions should be sent with payment to American Chemical Society, Department L-0011, Columbus, OH 43268-0011. Subscriptions are available only on a calendar year basis. Rates quoted do not apply to nonmember subscribers in Japan, who must enter subscription orders with Maruzen Company Ltd., 3-10 Nihonbashi 2-chome, Chuo-ku, Tokyo 103, Japan. Tel: (03) 272-7211.

Printed edition single issue prices: current year, \$20.00; prior year, \$45.00. Back volume price: \$531.00. Foreign postage additional. Mail orders should be sent to Microforms & Back Issues Office at the ACS Washington address.

Phone orders can be placed for printed, microfiche, and microfilm editions by calling the ACS toll free at (800) 333-9511 from anywhere in the United States and Canada; elsewhere call (614) 447-3776. Phone orders can be charged to Visa, MasterCard, or American Express accounts.

Changes of address must include both old and new addresses with ZIP code and a recent mailing label. Send all address changes to Member & Subscriber Services. Please allow 6 weeks for change to become effective.

Claims for missing numbers will not be allowed if loss was due to failure of notice of change of address to be received in the time specified; if claim is dated (a) North America—more than 90 days beyond issue date, (b) all other foreign— more than 180 days beyond issue date. Hard copy claims are handled by Member & Subscriber Services.

Supplementary material is noted in the table of contents with a \blacksquare . It is available as photocopy (\$10.00 for up to 3 pages and \$1.50 per page for additional pages, plus \$2.00 for foreign postage) or as 24× microfiche (\$10.00, plus \$1.00 for foreign postage). Canadian residents should add 7% GST. See supplementary material notice at end of journal article for number of pages. Orders *must* state whether for photocopy or for microfiche and give complete title of article, names of authors, journal, issue date, and page numbers. Prepayment is required and prices are subject to change. Order from Microforms & Back Issues Office at the ACS Washington address. Supplementary material except structure factors also appears in the microfilm edition and may be ordered by subscription (in microfiche

© Copyright 1992 by the American Chemical Society

Volume 35, Number 18 September 4, 1992 JMCMAR 35(18) 3307-3428 (1992) ISSN 0022-2623

COMMUNICATIONS TO THE EDITOR

3423 3-Phenyl-4-hydroxyquinolin-2(1*H*)-ones: Potent and Selective Antagonists at the Strychnine-Insensitive Glycine Site on the *N*-Methyl-D-aspartate Receptor Complex

Loretta A. McQuaid,* Edward C. R. Smith, David Lodge, Etienne Pralong, James H. Wikel, David O. Calligaro, and Patrick J. O'Malley

 Specific Inhibition of HIV-1 Protease by Boronated Porphyrins
 Dianne L. DeCamp, Lilia M. Babé, Rafael Salto, Jeanne L. Lucich, Myoung-Seo Koo, Stephen B. Kahl,* and Charles S. Craik*

ARTICLES

- 3307 Novel 5-HT₃ Antagonists. Isoquinolinones and 3-Aryl-2-pyridones Toshiaki Matsui, Tsuneyuki Sugiura, Hisao Nakai,* Sadahiko Iguchi, Satoshi Shigeoka, Hideo Takada, Yoshihiko Odagaki, Yuhki Nagao, Yasuyuki Ushio, Kazuyuki Ohmoto, Hiroyuki Iwamura, Shinichi Yamazaki, Yoshinobu Arai, and Masanori Kawamura
- 3319 Synthesis and Excitatory Amino Acid Pharmacology of a Series of Heterocyclic-Fused Quinoxalinones and Quinazolinones Loretta A. McQuaid,* Edward C. R. Smith, Kimberly K. South, Charles H. Mitch, Darryle D. Schoepp, Rebecca A. True, David O. Calligaro, Patrick J. O'Malley, David Lodge, and Paul L. Ornstein
- Synthesis and Pharmacological Studies of N-Substituted
 6-[(2-Aminoethyl)amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinediones, Novel Class III Antiarrhythmic Agents
 Tsutomu Katakami,* Tatsuro Yokoyama, Michihiko Miyamoto, Haruki Mori, Nobuya Kawauchi,
- Tsutomu Katakami,* Tatsuro Yokoyama, Michihiko Miyamoto, Haruki Mori, Nobuya Kawaucii, Tadahito Nobori, Kunio San-nohe, Tatsuo Kaiho,* and Joji Kamiya
- 3331 Synthesis of a Homologous Series of Ketomethylene Arginyl Pseudodipeptides and Application to Low Molecular Weight Hirudin-like Thrombin Inhibitors John DiMaio,* Bernard Gibbs, Jean Lefebvre, Yasuo Konishi, Debra Munn, Shi Yi Yue, and Wilfried Hornberger
- Betermination of the Absolute Configuration of the Active Amlodipine Enantiomer as (-)-S: A Correction
 Siegfried Goldmann,* Jürgen Stoltefuss, and Liborius Born
- 3344 Synthesis and Functional Evaluation of a Peptide Derivative of 1-β-D-Arabinofuranosylcytosine Zoltán Balajthy,* János Aradi, Ildikó T. Kiss, and Pál Elödi

Janet A. Houghton. Franklin C. Harwood, and Peter J. Houghton*

- 3349 cis-Bis(pyridine)platinum(II) Organoamides with Unexpected Growth Inhibition Properties and Antitumor Activity Lorraine K. Webster,* Glen B. Deacon,* David P. Buxton, Brian L. Hillcoat, Alison M. James, Ian A. G. Roos, Robin J. Thomson, Laurence P. G. Wakelin, and Tracey L. Williams
- 3353 Synthesis and Antibronchospastic Activity of 8-Alkoxy- and 8-(Alkylamino)imidazo[1,2-a]pyrazines Pierre A. Bonnet, Alain Michel, Florence Laurent, Claire Sablayrolles, Eliane Rechencq, Jean C. Mani, Maurice Boucard, and Jean P. Chapat*
- 3358 Synthesis and Chemical Characterization of N-Substituted Phenoxazines Directed toward Reversing Vinca Alkaloid Resistance in Multidrug-Resistant Cancer Cells Kuntebommanahalli N. Thimmaiah, Julie K. Horton, Ramakrishnan Seshadri, Mervyn Israel,

Find authenticated court documents without watermarks at docketalarm.com.

- 3364 Synthesis and Biological Activity of Ketomethylene Pseudopeptide Analogues as Thrombin Inhibitors Leifeng Cheng,* Christopher A. Goodwin, Michael F. Schully, Vijay V. Kakkar, and Göran Claeson*
- 3369 3',3'-Difluoro-3'-deoxythymidine: Comparison of Anti-HIV Activity to 3'-Fluoro-3'-deoxythymidine Donald E. Bergstrom,* Andrew W. Mott, Erik De Clercq, Jan Balzarini, and Daniel J. Swartling
- 3372 Synthesis and Antiviral Properties of (±)-5'-Noraristeromycin and Related Purine Carbocyclic Nucleosides. A New Lead for Anti-Human Cytomegalovirus Agent Design

Sharadbala D. Patil, Stewart W. Schneller,* Mitsuaki Hosoya, Robert Snoeck, Graciela Andrei, Jan Balzarini, and Erik De Clercq

- 3377 Antitumor Imidazotetrazines. 25. Crystal Structure of 8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one
- (Temozolomide) and Structural Comparisons with the Related Drugs Mitozolomide and DTIC P. R. Lowe, C. E. Sanson, C. H. Schwalbe,* M. F. G. Stevens, and A. S. Clark
- 3382 Energy Aspects of Oil/Water Partition Leading to the Novel Hydrophobic Parameters for the Analysis of Quantitative Structure-Activity Relationships

Yong-Zhong Da, Katsuhiko Ito, and Hideaki Fujiwara*

3388 Synthesis and Biological Evaluation of Dihydroeptastatin, a Novel Inhibitor of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase

Elisabeth A. Bone, Alan H. Davidson, Christopher N. Lewis,* and Richard S. Todd

- 3394 Non-Prostanoid Thromboxane A₂ Receptor Antagonists with a Dibenzoxepin Ring System. 1 Etsuo Ohshima, Hitoshi Takami, Hideyuki Sato, Hiroyuki Obase,* Ichiro Miki, Akio Ishii, Akira Karasawa, and Kazuhiro Kubo
- 3402 Non-Prostanoid Thromboxane A₂ Receptor Antagonists with a Dibenzoxepin Ring System. 2 Etsuo Ohshima, Hitoshi Takami, Hideyuki Sato, Shinichiro Mohri, Hiroyuki Obase,* Ichiro Miki, Akio Ishii, Shiro Shirakura, Akira Karasawa, and Kazuhiro Kubo
- 3413 Reversible Inhibitors of the Gastric (H⁺/K⁺)-ATPase. 3. 3-Substituted-4-(phenylamino)quinolines Robert J. Ife,* Thomas H. Brown, David J. Keeling, Colin A. Leach, Malcolm L. Meeson, Michael E. Parsons, David R. Reavill, Colin J. Theobald, and Kenneth J. Wiggall

■ Supplementary material for this paper is available separately (consult the masthead page for ordering information); all supplementary material except structure factor tables will also appear following the paper in the microfilm edition of this journal.

* In papers with more than one author, the asterisk indicates the name of the author to whom inquiries about the paper should be addressed.

AUTHOR INDEX

Andrei, G., 3372	Elödi, P., 3344	Katakami, T., 3325	Nagao, Y., 3307 Nakai, H., 3307	Shigeoka, S., 3307 Shirakura, S., 3402
Aradi, J., 3344 Arai, Y., 3307	Fujiwara, H., 3382	Kawamura, M., 3307 Kawauchi, N., 3325 Keeling, D. J., 3413	Nakai, H., 3307 Nobori, T., 3325	Smith, E. C. R., 3319, 3423
Babé, L. M., 3426 Balajthy, Z., 3344 Balzarini, J., 3369, 3372	Gibbs, B., 3331 Goldmann, S., 3341 Goodwin, C. A., 3364	Kiss, I. T., 3344 Konishi, Y., 3331 Koo, MS., 3426	Obase, H., 3394, 3402 Odagaki, Y., 3307 Ohmoto, K., 3307	Snoeck, R., 3372 South, K. K., 3319 Stevens, M. F. G., 3377 Stoltefuss, J., 3341
Bergstrom, D. E., 3369 Bone, E. A., 3388 Bonnet, P. A., 3353	Harwood, F. C., 3358 Hillcoat, B. L., 3349 Hornberger, W., 3331	Kubo, K., 3394, 3402 Laurent, F., 3353 Leach, C. A., 3413	Ohshima, E., 3394, 3402 O'Malley, P. J., 3319, 3423 Ornstein, P. L., 3319	Sugiura, T., 3307 Swartling, D. J., 3369
Born, L., 3341 Boucard, M., 3353 Brown, T. H., 3413 Buxton, D. P., 3349	Horton, J. K., 3358 Hosoya, M., 3372 Houghton, J. A., 3358	Lefebvre, J., 3331 Lewis, C. N., 3388 Lodge, D., 3319, 3423	Parsons, M. E., 3413 Patil, S. D., 3372 Pralong, E., 3423	Takada, H., 3307 Takami, H., 3394, 3402 Theobald, C. J., 3413 Thimmaiah, K. N., 3358
Calligaro, D. O., 3319, 3423	Houghton, P. J., 3358 Ife, R. J., 3413 Iguchi, S., 3307	Lowe, P. R., 3377 Lucich, J. L., 3426 Mani, J. C., 3353	Reavill, D. R., 3413 Rechencq, E., 3353	Thomson, R. J., 3349 Todd, R. S., 3388 True, R. A., 3319
Chapat, J. P., 3353 Cheng, L., 3364 Claeson, G., 3364	Ishii, A., 3394, 3402 Israel, M., 3358 Ito, K., 3382	Matsui, T., 3307 McQuaid, L. A., 3319, 3423	Roos, I. A. G., 3349 Sablayrolles, C., 3353	Ushio, Y., 3307 Wahalim L. P. C. 2349
Clark, A. S., 3377 Craik, C. S., 3426	Iwamura, H., 3307 James, A. M., 3349	Meeson, M. L., 3413 Michel, A., 3353 Miki, I., 3394, 3402	Salto, R., 3426 San-nohe, K., 3325 Sansom, C. E., 3377 Sata H. 3304, 3402	Wakelin, L. P. G., 3349 Webster, L. K., 3349 Wiggall, K. J., 3413 Wikel, J. H., 3423
Da, YZ., 3382 Davidson, A. H., 3388 Deacon, G. B., 3349	Kahl, S. B., 3426 Kaiho, T., 3325	Mitch, C. H., 3319 Miyamoto, M., 3325 Mohri, S., 3402	Sato, H., 3394, 3402 Schneller, S. W., 3372 Schoepp, D. D., 3319 Schully, M. F., 3364	Williams, T. L., 3349 Yamazaki, S., 3307
DeCamp, D. L., 3426 De Clercq, E., 3369, 3372 DiMaio, J., 3331	Kakkar, V. V., 3364 Kamiya, J., 3325 Karasawa, A., 3394, 3402	Mori, H., 3325 Mott, A. W., 3369 Munn, D., 3331	Schwalbe, C. H., 3377 Seshadri, R., 3358	Yokoyama, T., 3325 Yue, S. Y., 3331

Find authenticated court documents without watermarks at docketalarm.com.

DOCKE.

Specific Inhibition of HIV-1 Protease by **Boronated Porphyrins**

The rapid spread of human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS), throughout the world has prompted an intense search for antiretroviral therapeutics. An analysis of nonpeptide compounds with useful pharmacological properties led us to test the ability of porphyrins to inhibit HIV protease (HIV PR). Determination of the IC₅₀'s of natural porphyrins on purified recombinant HIV-1 and HIV-2 PRs revealed that they are micromolar inhibitors of these enzymes. Availability of a series of carboxyl carborane ester derivatives of porphyrins synthesized as experimental neutron-capture therapeutics led to the discovery that compound 1, the tetrakiscarborane carboxylate ester of 2,4-bis- $(\alpha,\beta$ -dihydroxyethyl)deutero-porphyrin IX^{1,2} Table I), is a submicromolar inhibitor of HIV protease. This compound is also capable of inhibiting HIV-1 viral polyprotein processing in cultured mammalian cells (ex vivo).

The in vitro effect of the porphyrin derivatives on HIV-1 and HIV-2 PR activity was examined by monitoring the cleavage of a decapeptide substrate.³ The IC₅₀ values for a series of porphyrin-based compounds measured on HIV-1 and HIV-2 PRs are shown in Table I. Since many of the derivatives were insoluble in buffer alone, 5% DMSO was used to increase solubility and to allow a comparison of the binding affinities of the various compounds. The best inhibitor is 1, with an IC_{50} of 185 nM for HIV-1 PR and 700 nM for HIV-2 PR. The inhibitory potency of the porphyrin derivatives for HIV-2 PR is generally a factor of 2-5 less than for HIV-1 PR. Dipotassium salts of several of the inhibitors were soluble in aqueous solution and were assayed in the absence of DMSO. The IC₅₀ values are shown in Table II.

The photosensitivity of 1 made the metalloporphyrin derivatives (3, 5, and 6) preferable for subsequent kinetic analysis. These were easily prepared in high yield by standard techniques, as described in the supplementary material. Initial enzyme rates were fit to the Michaelis-Menten equation and kinetic constants were calculated using a nonlinear regression program.⁴ A Dixon plot for 5 is shown in Figure 1. The appearance of the intersecting inhibition curves is consistent with a competitive mode of inhibition, with an inhibition constant (K_i) of 140 ± 25 nM. Compound 3 also appears to be a competitive inhibitor, with a K_i of 85 ± 5 nM (data not shown). The effect of salt concentration on inhibition by 3 was examined. The IC₅₀ in 0.3 M NaCl (85 nM) was similar to the value obtained with 1 M NaCl (100 nM). This low ionic strength dependence of inhibition is important for in vivo applications.

The compounds assayed can be divided into three

- (2) Kahl, S. B.; Koo, M.-S. Synthesis of Tetrakis-carborane-carboxylate Esters of 2,4-Bis- $(\alpha,\beta$ -dihydroxyethyl)-deuteroporphyrin IX. J. Chem. Soc., Chem. Commun. 1990, 24, 1769 - 1771.
- (3) DesJarlais, R. L.; Seibel, G. L.; Kuntz, I. D.; Furth, P. S.; Alvarez, J. C.; Ortiz de Montellano, P. R.; DeCamp, D. L.; Babé, L. M.; Craik, C. S. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 6644-6648.
- Leatherbarrow, R. J. Enzfitter. A Non-linear Regression Data (4)Analysis Program for the IBM-PC. Elsevier Biosoft, Cambridge, U.K, 1987.




Figure 1. Dixon plot of 5 inhibition of HIV-1 PR. Purified HIV-1 PR (6 \times 10⁻⁴ mg/mL) was incubated with 5 in 50 mM sodium acetate buffer, pH 5.5, containing 1 mM dithiothreitol, 1 mM EDTA, and 1 M NaCl. After 1 min, the substrate peptide was added to give the final substrate concentrations shown. The assay solutions were incubated for 30-45 min at 37 °C and enzyme activity was determined by quantitation of the hydrolysis products on HPLC.

classes: (1) carborane esters, (2) noncarborane esters, and (3) protoporphyrin IX. The best inhibitor in vitro is 1, which is esterified with four molecules of 1,2-dicarba-closo-dodecaboranecarboxylic acid. Although complexation with Co(II) or Cu(II) weakens binding about 10-fold, addition of Mn(III) has only 2-fold effect on inhibition, indicating that the hexacoordinate Mn(III) may be able to make favorable ionic interactions with the enzyme. Removal of all four carborane moieties, as in 12, substantially reduces inhibition. Removal of only two cages, as in 2, has little effect on binding. This suggests that only two of the four *closo*-carborane cages are responsible for most of the binding interaction. The metacarborane isomer, 9, binds approximately 60-fold less tightly, indicating that not only the presence of the carborane groups but also their isomeric conformation is important. Adding a methyl group to the unsubstituted carborane cage CH, as in 4, also substantially decreases the binding affinity. The carborane cages thus appear to have a specific interaction with HIV PR which results in high affinity between the molecule and enzyme. Replacement of the carborane cages with similarly sized but less hydrophobic groups such as benzoyl (10), adamantoyl (7), or even β -napthoyl (11) groups gives inhibitors with IC₅₀ values in the low micromolar range, suggesting the importance of supplying hydrophobic groups at these positions. The effect of the porphyrin derivatives on HIV-2 PR generally follows the same trend, with most of the IC_{50} values being several-fold higher.

The cytotoxicity of compounds (LD_{50}) and their ability to inhibit capsid protein processing ex vivo during 4-h incubations (IC_{50}) are shown in Table I. A plasmid which encodes the HIV-1 proviral genome, with the exception of the gp 160 envelope protein,⁵ was stably introduced into the monkey cell line COS 7. Cloned progeny, COS A6 cells, constitutively release viral capsids into the media. Inhibition of polyprotein processing was determined by measuring the amount of p24 present in the viral capsid samples with an ELISA assay. The decrease in the amount of detectable p24 antigen correlated with a specific inhibition of HIV PR activity, as judged by the accumulation of capsid precursor in conjunction with a disappearance of the p24 mature protein band in Western blots (data not

0022-2623/92/1835-3426\$03.00/0 © 1992 American Chemical Society

⁽¹⁾ Hill, J. S.; Kahl, S. B.; Kaye, A. H.; Stylli, S. S.; Koo, M.-S.; Gonzales, M. F.; Vardaxis, N. J.; Johnson, C. I. Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. Proc. Natl. Sci. U.S.A. 1992, 89, 1785-1789.

Page, K. A.; Landau, N. R.; Littman, D. R. Construction and (5) use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol. 1990, 64, 5270-5276.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.